Sign In
Last checked at 
1 May 2020 07:00
Ā 1 May 2020
RTW VENTURE FUND LIMITED(the "Company")
Ā
TOTAL VOTING RIGHTS
Ā
In accordance with DTR 5.6.1R, as at 30 April 2020 the Company had 177,384,731 Ordinary Shares in issue, each with equal voting rights, and no shares held in Treasury.
Ā
This total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Ā
RTW Investments, LP Stephanie Sirota, Chief Business OfficerAlexandra Taracanova, PhD, Director of Investor Relations Julia Enright, Business Development Associate Ā Ocorian Administration (Guernsey) Limited Kevin Smith Ā | +1 (646) 343 9280 Ā Ā +44 (0) 1481 742 642 Ā |
J.P. Morgan Cazenove William Simmonds Oliver Kenyon James Bouverat (Sales) Ā Barclays Tom Swerling Andrew Tusa Ryan McCarthy Ā | +44 (0)20 7742 4000 Ā Ā +44 (0)20 7623 2323 |
Ā
About RTW Venture Fund Limited:
RTW Venture Fund Limited (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.
Ā
RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Ā
Visit the RTW website at www.rtwfunds.com for more information.
Ā
Ā
Follow the stocks
